AU2016326510C1 - Methods of treating intraocular pressure with activators of Tie-2 - Google Patents

Methods of treating intraocular pressure with activators of Tie-2 Download PDF

Info

Publication number
AU2016326510C1
AU2016326510C1 AU2016326510A AU2016326510A AU2016326510C1 AU 2016326510 C1 AU2016326510 C1 AU 2016326510C1 AU 2016326510 A AU2016326510 A AU 2016326510A AU 2016326510 A AU2016326510 A AU 2016326510A AU 2016326510 C1 AU2016326510 C1 AU 2016326510C1
Authority
AU
Australia
Prior art keywords
group
compound
mmhg
tie
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016326510A
Other languages
English (en)
Other versions
AU2016326510B2 (en
AU2016326510A1 (en
Inventor
Kevin Gene Peters
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EyePoint, Inc.
Original Assignee
Eyepoint Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eyepoint Pharmaceuticals Inc filed Critical Eyepoint Pharmaceuticals Inc
Publication of AU2016326510A1 publication Critical patent/AU2016326510A1/en
Assigned to Aerpio Pharmaceuticals, Inc. reassignment Aerpio Pharmaceuticals, Inc. Request for Assignment Assignors: AERPIO THERAPEUTICS, INC.
Assigned to EyePoint Pharmaceuticals, Inc. reassignment EyePoint Pharmaceuticals, Inc. Request for Assignment Assignors: Aerpio Pharmaceuticals, Inc.
Application granted granted Critical
Publication of AU2016326510B2 publication Critical patent/AU2016326510B2/en
Priority to AU2022202618A priority Critical patent/AU2022202618B2/en
Publication of AU2016326510C1 publication Critical patent/AU2016326510C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2016326510A 2015-09-23 2016-09-22 Methods of treating intraocular pressure with activators of Tie-2 Active AU2016326510C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022202618A AU2022202618B2 (en) 2015-09-23 2022-04-20 Methods of treating intraocular pressure with activators of Tie-2

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562222481P 2015-09-23 2015-09-23
US62/222,481 2015-09-23
PCT/US2016/053107 WO2017053566A1 (en) 2015-09-23 2016-09-22 Methods of treating intraocular pressure with activators of tie-2

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022202618A Division AU2022202618B2 (en) 2015-09-23 2022-04-20 Methods of treating intraocular pressure with activators of Tie-2

Publications (3)

Publication Number Publication Date
AU2016326510A1 AU2016326510A1 (en) 2018-04-12
AU2016326510B2 AU2016326510B2 (en) 2022-03-10
AU2016326510C1 true AU2016326510C1 (en) 2024-06-27

Family

ID=58276474

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016326510A Active AU2016326510C1 (en) 2015-09-23 2016-09-22 Methods of treating intraocular pressure with activators of Tie-2
AU2022202618A Active AU2022202618B2 (en) 2015-09-23 2022-04-20 Methods of treating intraocular pressure with activators of Tie-2

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022202618A Active AU2022202618B2 (en) 2015-09-23 2022-04-20 Methods of treating intraocular pressure with activators of Tie-2

Country Status (15)

Country Link
US (3) US10952992B2 (cg-RX-API-DMAC7.html)
EP (3) EP4414032A3 (cg-RX-API-DMAC7.html)
JP (3) JP6959924B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180054677A (cg-RX-API-DMAC7.html)
CN (2) CN108290057A (cg-RX-API-DMAC7.html)
AU (2) AU2016326510C1 (cg-RX-API-DMAC7.html)
BR (1) BR112018005499A2 (cg-RX-API-DMAC7.html)
CA (1) CA2998673C (cg-RX-API-DMAC7.html)
ES (2) ES2981607T3 (cg-RX-API-DMAC7.html)
IL (1) IL258150B (cg-RX-API-DMAC7.html)
MX (2) MX387804B (cg-RX-API-DMAC7.html)
MY (1) MY194736A (cg-RX-API-DMAC7.html)
PH (1) PH12018500658A1 (cg-RX-API-DMAC7.html)
SG (1) SG10201912000WA (cg-RX-API-DMAC7.html)
WO (1) WO2017053566A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7973142B2 (en) 2006-04-07 2011-07-05 Warner Chilcott Company Antibodies that bind human protein tyrosine phosphatase beta (HPTPβ)
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
MX2011007420A (es) 2009-07-06 2011-12-14 Akebia Therapeutics Inc Compuestos, composiciones y metodos para prevenir la metastasis de las celulas cancerigenas.
EP3505182A1 (en) 2011-10-13 2019-07-03 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
EP4414032A3 (en) 2015-09-23 2024-11-06 EyePoint Pharmaceuticals, Inc. Methods of treating intraocular pressure with activators of tie-2
CN109715189B (zh) 2016-07-20 2025-01-03 视点制药公司 靶向VE-PTP(HPTP-β)的人源化单克隆抗体
US20210283051A1 (en) * 2018-07-13 2021-09-16 Mannin Research, Inc. Ve-ptp inhibition in glaucoma
AU2020259450A1 (en) * 2019-04-18 2021-11-18 EyePoint Pharmaceuticals, Inc. Methods of treating hypertension with activators of Tie-2
AU2020264969B2 (en) * 2019-04-29 2025-06-05 EyePoint, Inc. Tie-2 activators targeting the schlemm's canal
GB2589400A (en) * 2019-06-24 2021-06-02 Aerpio Pharmaceuticals Inc Formulations of tie-2 activators and methods of use thereof
CA3156225A1 (en) 2019-10-29 2021-05-06 EyePoint Pharmaceuticals, Inc. Small molecule activators of tie-2
CA3162689A1 (en) * 2020-01-08 2021-07-15 Kevin Peters Combinations of tie-2 activators and prostaglandins and uses thereof

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US645503A (en) 1899-05-11 1900-03-13 Timothy Francis Crowley Cutter-gage for ice-cream, & c.
US953924A (en) 1909-06-28 1910-04-05 Dow Wire & Iron Works Sliding door.
US20030040463A1 (en) 1996-04-05 2003-02-27 Wiegand Stanley J. TIE-2 ligands, methods of making and uses thereof
AU5154098A (en) 1996-10-31 1998-05-22 Duke University Soluble tie2 receptor
US5919813C1 (en) 1998-03-13 2002-01-29 Univ Johns Hopkins Med Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy
US5980929A (en) 1998-03-13 1999-11-09 Johns Hopkins University, School Of Medicine Use of a protein tyrosine kinase pathway inhibitor in the treatment of retinal ischmemia or ocular inflammation
US6455035B1 (en) 1999-03-26 2002-09-24 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of use thereof
DE60003011T2 (de) 1999-03-26 2004-04-08 Regeneron Pharmaceuticals, Inc. Modulierung der gefässepermeabilität mittels tie2 rezeptoraktivatoren
EP1046715A1 (en) 1999-04-23 2000-10-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Interaction of vascular-endothelial protein-tyrosine phosphatase with the angiopoietin receptor tie-2
US6897201B2 (en) * 2000-08-21 2005-05-24 Inspire Pharmaceuticals, Inc. Compositions and methods for the treatment of glaucoma or ocular hypertension
US7052695B2 (en) 2001-10-25 2006-05-30 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of treating hypertension
WO2003084565A2 (en) 2002-04-08 2003-10-16 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Ve-ptp as regulator of ve-cadherin mediated processes or disorders
WO2003090686A2 (en) 2002-04-25 2003-11-06 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
US7507568B2 (en) 2002-09-25 2009-03-24 The Proctor & Gamble Company Three dimensional coordinates of HPTPbeta
US7226755B1 (en) 2002-09-25 2007-06-05 The Procter & Gamble Company HPTPbeta as a target in treatment of angiogenesis mediated disorders
AR046510A1 (es) 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
US8298532B2 (en) 2004-01-16 2012-10-30 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
MXPA06010642A (es) 2004-03-15 2007-03-26 Johnson & Johnson Compuestos novedosos como moduladores del receptor opioi.
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
PT1771474E (pt) 2004-07-20 2010-05-03 Genentech Inc Inibidores de proteína 4 do tipo angiopoietina, combinações e sua utilização
EP1819355A4 (en) 2004-09-28 2009-08-12 Genexel Sein Inc METHOD OF USE OF A CHIMERIC COILED COIL MOLECULE
CN101128483B (zh) 2004-12-21 2015-06-03 阿斯利康公司 血管生成素-2的抗体及其应用
US7893040B2 (en) 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
WO2007033216A2 (en) 2005-09-12 2007-03-22 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
TW200744567A (en) * 2005-09-23 2007-12-16 Alcon Inc Phenylethylamine analogs and their use for treating glaucoma
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
AU2006324477A1 (en) 2005-12-15 2007-06-21 Medimmune Limited Combination of angiopoietin-2 antagonist and of VEGF-A, KDR and/or Flt1 antagonist for treating cancer
CN104623692A (zh) 2006-03-08 2015-05-20 阿切埃米克斯股份有限公司 治疗视觉失调中使用的补体结合适体和抗-c5药物
US7973142B2 (en) 2006-04-07 2011-07-05 Warner Chilcott Company Antibodies that bind human protein tyrosine phosphatase beta (HPTPβ)
DE102006016426A1 (de) * 2006-04-07 2007-10-11 Merck Patent Gmbh Neuartige Cyclobutyl-Verbindungen als Kinase-Inhibitoren
US20130023542A1 (en) 2006-06-27 2013-01-24 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US8846685B2 (en) 2006-06-27 2014-09-30 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US7795444B2 (en) 2006-06-27 2010-09-14 Warner Chilcott Company Human protein tyrosine phosphatase inhibitors and methods of use
US7589212B2 (en) 2006-06-27 2009-09-15 Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
WO2008049227A1 (en) 2006-10-27 2008-05-02 Sunnybrook Health Sciences Center Multimeric tie 2 agonists and uses thereof in stimulating angiogenesis
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
US11078262B2 (en) 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
CA2716347C (en) 2008-02-21 2017-06-20 Sequoia Pharmaceuticals, Inc. Amino acid inhibitors of cytochrome p450
US9096555B2 (en) 2009-01-12 2015-08-04 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome
RU2014146121A (ru) 2009-01-12 2015-06-10 Аэрпио Терапьютикс Инк. Способы лечения синдрома сосудистой утечки
WO2010097800A1 (en) 2009-02-26 2010-09-02 Muhammad Abdulrazik Synergistic combination of bioactive compounds for lowering of intraocular pressure
KR20110123789A (ko) 2009-03-03 2011-11-15 알콘 리서치, 리미티드 리셉터 티로신 키나제 저해(ＲＴＫｉ) 화합물을 눈에 전달하기 위한 약학 조성물
KR20160135372A (ko) 2009-03-03 2016-11-25 알콘 리서치, 리미티드 리셉터 티로신 키나제 저해(ＲＴＫｉ) 화합물을 눈에 전달하기 위한 약학 조성물
MX2011007420A (es) 2009-07-06 2011-12-14 Akebia Therapeutics Inc Compuestos, composiciones y metodos para prevenir la metastasis de las celulas cancerigenas.
US8883832B2 (en) 2009-07-06 2014-11-11 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
MX2012014428A (es) 2010-07-12 2013-03-05 Threshold Pharmaceuticals Inc Administracion de profarmacos activados por hipoxia y de agentes antiangiogenicos para el tratamiento de cancer.
US20180092883A1 (en) 2010-10-07 2018-04-05 Aerpio Therapeutics, Inc. Phosphatase inhibitors for treating ocular diseases
BR112013008452A2 (pt) 2010-10-07 2016-06-28 Aerpio Therapeutics Inc composição e métodos de tratamento de edema ocular, neovascularização e doenças relacionadas
CN103249422A (zh) 2010-12-02 2013-08-14 丸善制药株式会社 Tie2活化剂、血管内皮生长因子抑制剂、血管生成抑制剂、血管成熟剂、血管正常化剂及血管稳定剂、以及药物组合物
EP3505182A1 (en) 2011-10-13 2019-07-03 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
HK1201438A1 (en) 2011-10-13 2015-09-04 Aerpio Therapeutics, Inc. Treatment of ocular disease
US20130190324A1 (en) 2011-12-23 2013-07-25 The Regents Of The University Of Colorado, A Body Corporate Topical ocular drug delivery
US20150071941A1 (en) 2012-04-13 2015-03-12 The Johns Hopkins University Treatment of ischemic retinopathies
RS57704B1 (sr) 2012-07-13 2018-12-31 Roche Glycart Ag Bispecifična anti-vegf/anti-ang-2 antitela i njihova primena u lečenju vaskularnih bolesti oka
PL2880167T3 (pl) 2012-07-31 2018-12-31 The Board Of Regents Of The University Of Texas System Sposoby i kompozycje do indukcji tworzenia trzustkowych komórek beta in vivo
NZ706853A (en) 2012-10-11 2018-04-27 Ascendis Pharma Ophthalmology Div A/S Vegf neutralizing prodrugs for the treatment of ocular conditions
CN110893188A (zh) 2012-11-08 2020-03-20 克莱尔塞德生物医学股份有限公司 用于在人类受试者中治疗眼部疾病的方法和装置
US20150290235A1 (en) 2012-11-23 2015-10-15 Ab Science Use of small molecule inhibitors/activators in combination with (deoxy)nucleoside or (deoxy)nucleotide analogs for treatment of cancer and hematological malignancies or viral infections
US9440963B2 (en) 2013-03-15 2016-09-13 Aerpio Therapeutics, Inc. Compositions, formulations and methods for treating ocular diseases
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
CA2909080C (en) 2013-04-11 2022-07-26 Sunnybrook Research Institute Methods, uses and compositions of tie2 agonists
WO2014203183A1 (en) 2013-06-20 2014-12-24 Novartis Ag Use of a vegf antagonist in treating macular edema
WO2014203182A1 (en) 2013-06-20 2014-12-24 Novartis Ag Use of a vegf antagonist in treating choroidal neovascularisation
US20160151410A1 (en) 2013-07-02 2016-06-02 The Trustees Of Columbia University In The City Of New York Clearance of bioactive lipids from membrane structures by cyclodextrins
RU2676303C2 (ru) 2013-07-11 2018-12-27 Новартис Аг Использование антагониста vegf для лечения ретролентальной фиброплазии
AU2014288837A1 (en) 2013-07-11 2015-12-10 Novartis Ag Use of a VEGF antagonist in treating chorioretinal neovascular and permeability disorders in paediatric patients
EP2832746B1 (en) 2013-07-29 2018-07-18 Samsung Electronics Co., Ltd Anti-Ang2 antibody
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
CA2925936A1 (en) 2013-10-01 2015-04-09 Sphingotec Gmbh A method for predicting the risk of getting a major adverse cardiac event
SMT201900295T1 (it) 2013-11-01 2019-07-11 Regeneron Pharma Interventi a base di angiopoietina per il trattamento della malaria cerebrale
CN106456614A (zh) * 2014-03-14 2017-02-22 爱尔皮奥治疗有限公司 HPTP‑β抑制剂
JP2015199733A (ja) * 2014-04-04 2015-11-12 国立大学法人東北大学 眼圧降下剤
CN106163946B (zh) 2014-04-04 2018-12-21 株式会社大造 排出容器
US9719135B2 (en) 2014-07-03 2017-08-01 Mannin Research Inc. Conditional angiopoietin-1/angiopoietin-2 double knock-out mice with defective ocular drainage system
WO2016022813A1 (en) 2014-08-07 2016-02-11 Aerpio Therapeutics, Inc. Combination of immunotherapies with activators of tie-2
WO2016049183A1 (en) 2014-09-24 2016-03-31 Aerpio Therapeutics, Inc. Ve-ptp extracellular domain antibodies delivered by a gene therapy vector
TWI806150B (zh) 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
US20160144025A1 (en) 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
EP4414032A3 (en) * 2015-09-23 2024-11-06 EyePoint Pharmaceuticals, Inc. Methods of treating intraocular pressure with activators of tie-2
AU2020264969B2 (en) * 2019-04-29 2025-06-05 EyePoint, Inc. Tie-2 activators targeting the schlemm's canal

Also Published As

Publication number Publication date
EP3352856A1 (en) 2018-08-01
CN113713101B (zh) 2023-07-28
EP4414032A2 (en) 2024-08-14
CA2998673A1 (en) 2017-03-30
MY194736A (en) 2022-12-15
JP2022000482A (ja) 2022-01-04
ES2981607T3 (es) 2024-10-09
EP3352856B1 (en) 2021-08-18
EP3352856A4 (en) 2019-05-01
MX387804B (es) 2025-03-19
US20210386713A1 (en) 2021-12-16
MX2021010915A (es) 2021-10-01
IL258150B (en) 2021-06-30
AU2022202618B2 (en) 2023-12-14
US12171751B2 (en) 2024-12-24
JP2024061772A (ja) 2024-05-08
CA2998673C (en) 2023-12-12
AU2016326510B2 (en) 2022-03-10
US20170079959A1 (en) 2017-03-23
AU2022202618A1 (en) 2022-05-12
NZ780430A (en) 2024-09-27
CN113713101A (zh) 2021-11-30
EP3977994A1 (en) 2022-04-06
EP4414032A3 (en) 2024-11-06
MX2018003542A (es) 2018-11-09
JP7451472B2 (ja) 2024-03-18
JP2018528273A (ja) 2018-09-27
AU2016326510A1 (en) 2018-04-12
US11666558B2 (en) 2023-06-06
CN108290057A (zh) 2018-07-17
US20230398100A1 (en) 2023-12-14
IL258150A (en) 2018-05-31
SG10201912000WA (en) 2020-02-27
WO2017053566A1 (en) 2017-03-30
JP6959924B2 (ja) 2021-11-05
PH12018500658A1 (en) 2018-10-01
EP3977994C0 (en) 2024-04-24
EP3977994B1 (en) 2024-04-24
NZ740730A (en) 2024-07-26
KR20180054677A (ko) 2018-05-24
BR112018005499A2 (pt) 2018-10-09
US10952992B2 (en) 2021-03-23
ES2894802T3 (es) 2022-02-15

Similar Documents

Publication Publication Date Title
AU2022202618B2 (en) Methods of treating intraocular pressure with activators of Tie-2
JP6865254B2 (ja) 眼疾患を処置するための組成物、製剤、および方法
US20210212998A1 (en) Combinations of Tie-2 Activators and Prostaglandins and Uses Thereof
HK40072252A (en) Activators of tie-2 for use in treating intraocular pressure
HK40072252B (en) Activators of tie-2 for use in treating intraocular pressure

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: AERPIO PHARMACEUTICALS, INC.

Free format text: FORMER APPLICANT(S): AERPIO THERAPEUTICS, INC.

PC1 Assignment before grant (sect. 113)

Owner name: EYEPOINT PHARMACEUTICALS, INC.

Free format text: FORMER APPLICANT(S): AERPIO PHARMACEUTICALS, INC.

FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 15 FEB 2024

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 15 FEB 2024